Healthcare's core malady: patients pay but have never been true customers
Ro founder argues healthcare spending is inevitable—the real problem is patients never being true customers. GLP-1's cash-pay model proves what works when they control the payment.
The video won't play here. Listen to the audio instead:
The argument · tap a timestamp to hear it
Patients can't become customers when others control healthcare payment
Patients' out-of-pocket expenses represent only a small fraction of total healthcare costs; employers and taxpayers pay the bulk. This means whoever controls the payment flow—not patients—determines what services healthcare offers. Only in cash-pay markets like LASIK and cosmetic surgery do prices fall and quality improve, because those customers face direct consequences. GLP-1 proves the principle: when patients pay themselves, the market works like any consumer market, with drugmakers competing on price and convenience.
— Zach ReitanoBypass middlemen: prices fall, volumes surge, total profit grows
GLP-1 manufacturers sell directly to consumers, bypassing both PBM and insurers. A drug with list price of $1,300 reaches patients for $149. He compares PBMs to an appendix—possibly once useful, but nobody remembers what problem they solved, and software can do their work if removed. The counterintuitive part: as prices drop, volume rises so much that total manufacturer revenue increases, not decreases. This proves patient control simultaneously lowers prices and grows the entire market.
— Zach ReitanoProven safety should deploy even if workers lose employment
Autonomous vehicles are 10 to 20 times safer than human drivers. The U.S. sees approximately 40,000 car-crash deaths annually—roughly equal to breast cancer deaths. Yet public debate centers on driver unemployment, not accelerating deployment of the solution. His view is unambiguous: when a technology is proven far safer, society should not delay it to protect old jobs. Those who block it bear responsibility for preventable deaths that follow. He worries healthcare will make the same mistake—prioritizing who delivers care over whether patients survive.
— Zach ReitanoWhen employees debate packaging, the company has surrendered already
In early 2022, Ro had closed a $500 million round at $5 billion valuation less than a year earlier, but grew only 9% that year—becoming a 'zombie company' that neither thrives nor collapses. The turning point came when employees complained on Slack about holiday macarons in plastic packaging. He realized winning companies simply don't care about packaging: 'We are, literally and figuratively, a company as soft as a macaron.' He wrote a six-page memo, cut approximately seven VPs and 20% of staff (reducing the team from over 600 to 400), and revenue subsequently became ten times larger.
— Zach ReitanoPlans longer than two years are fiction, not strategy
Ro eliminated long-term roadmaps entirely, calling them 'false precision'—like printing directions instead of using Google Maps. Any new variable (a new drug, regulation, or AI breakthrough) invalidates everything from step three onward. Instead, the company held daily 8:50 a.m. all-hands standups with leadership for two consecutive years, forcing every person to show progress within 24 hours rather than waiting until Monday. They also deliberately sequenced work—tackling one thing at a time—rather than parallelizing, because compounding returns from undivided focus dwarf the benefits of pushing five initiatives forward simultaneously.
— Zach ReitanoTwenty years from discovery to treatment reveals medicine's broken cycles
The Dallas Heart Study in 2000 tracked 3,500 patients. In 2006, researchers discovered a subset carried a 'defective' PCSK9 gene that kept their LDL cholesterol at 30 to 40, reducing heart disease risk by 85% to 90% regardless of smoking, drinking, or eating hamburgers. Merck launched an oral drug mimicking this genetic effect this year—a gap of nearly 20 years from discovery to treatment. He sees medicine-AI fusion's best opportunity in compressing feedback cycles: mathematics and programming enjoy structured data and rapid feedback, but medicine's feedback is death and disease—slow and chaotic. The cycle from discovery to therapy must be radically shortened.
— Zach ReitanoThe fiercer the backlash, the more suppressed demand exists
Ro's early subway advertisements simply showed eligible people using GLP-1 injections for weight loss. The campaign triggered enormous backlash—people felt uncomfortable with 'injection weight loss' while underestimating obesity's health harms. He interprets fierce negative reactions as a signal: the greater the criticism, the more demand the market is suppressing. His standard for pushing through controversy is 'moral high ground'—if history will eventually vindicate the decision, amplify the message maximally. This logic drove Ro to recruit Serena Williams and Megan Fox to normalize GLP-1 use in a field burdened by stigma.
— Zach ReitanoA father's dying wish taught him to end with love
While Zach was at boarding school and homesick, he was short with his parents during a visit. As they left, his father—unusually—had his mother drive while he sat in the passenger seat, rolled down the window, and asked, 'Tell me you love me.' Zach immediately replied that he loved them. Years later, Zach learned his father was experiencing his fourth heart attack at that moment and thought he might not survive; he wanted his last words to be 'I love you,' not an argument. The experience became habit-forming: Zach now says 'I love you' before ending every phone call—with friends, family, and business partners alike.
— Zach ReitanoIn their own words · checked verbatim
It is that the patient is not the customer. That's the problem that we're trying to solve at Roe.
Zach Reitano6:19
You have $1,300 drugs that people are paying behind the scenes $300, $400 for.
Zach Reitano7:22
PBMs, to me, they are like the appendix of the healthcare system. At one point in time, they might have served some purpose, but it was so long ago that people can't remember what the heck it was.
Zach Reitano8:25
about 40,000 people a year die from car accidents. That is almost the same exact numbers that people who die from breast cancer every single year.
Zach Reitano23:42
I do believe that the people impeding driverless cars where they're proven to be safe should have a body count attached to their name.
Zach Reitano24:44
We were literally and figuratively. We were macaroon soft. We were a soft company.
Zach Reitano30:57
Spending a lot of time on long term roadmaps is like printing out map requests instead of using Google Maps. It is false precision.
Zach Reitano42:10
I wanted them to be, I love you.
Zach Reitano1:14:07
Figures
| US healthcare as % of GDP | Increased from 9% to 18% | 3:13 |
| UK healthcare as % of GDP | Increased from 6% to 12% | 3:13 |
| Germany healthcare as % of GDP | Increased from 9% to 12% | 3:13 |
| Ro team size | Reduced from over 600 to 400 | 36:05 |
| GLP-1 cash-pay price | Dropped from $1,300 to $149 | 8:25 |
| Repatha cash-pay price | Dropped from $600/month to $200/month | 51:28 |
| Ro funding (January 2021) | $500 million at $5 billion valuation | 29:53 |
| GLP-1 usage in 10 years (Zach's prediction) | 50% or more of population | 21:37 |
Glossary
- PBM
- Middleman between pharmaceutical manufacturers and insurers; commonly blamed for raising drug prices and obscuring pricing.
- Overton window
- The range of ideas society finds acceptable; shifts as advocates push the boundaries.
- Demand aggregator
- Business model aggregating dispersed individual demand and matching it to suppliers, such as Costco-style membership.
- Strong attract, strong repel
- Company culture sufficiently clear that aligned people strongly commit while misaligned people self-select out.
How to listen
Founders and investors focused on healthcare startups, GLP-1 business logic, consumer-brand strategy, or organizational restructuring.
Personal medication details from 46:27 onward; optional to skip.